Interim Results for the six months ended 31 December 2021 Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...

Allergy Therapeutics plc - Successful litigation settlement relating to PQ Grass Phase II Trial Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the...

Allergy Therapeutics plc - Trading Update and Successful Litigation Settlement Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Trading Update and Successful Litigation Settlement  2019 full year earnings expected to be ahead of market expectations 27 June...

Allergy Therapeutics PLC: Trading Update Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”)  Trading update Group’s market share continues to grow 12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated...

Allergy Therapeutics plc - Positive new data with house-dust mite immunotherapy Allergy Therapeutics plc("Allergy Therapeutics", the “Group” or “Company") Positive new clinical data with house-dust mite immunotherapy ~ House-dust mite immunotherapy shown to be well-tolerated...